Search Results - "Tibben, J G"

Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration by Buijs, W C, Tibben, J G, Boerman, O C, Molthoff, C F, Massuger, L F, Koenders, E B, Schijf, C P, Siegel, J A, Corstens, F H

“…In this study the potential of intraperitoneal (i.p.) and intravenous (i.v.) administration of chimeric iodine-131-labelled MOv18 IgG for radioimmunotherapy…”
Get full text

Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer by Boerman, O C, Tibben, J G, Massuger, L F, Claessens, R A, Corstens, F H

“…The anti-tumour x anti-T-cell bispecific monoclonal antibody (biMAb) OC/TR is a biologically produced biMAb combining the anti-ovarian carcinoma activity of…”
Get more information

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2 by Tibben, J G, Boerman, O C, Claessens, R A, Corstens, F H, van Deuren, M, de Mulder, P H, van der Meer, J W, Keijser, K G, Massuger, L F

Get more information

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab')2 in experimental ovarian cancer by Tibben, J G, Massuger, L F, Boerman, O C, Borm, G F, Claessens, R A, Corstens, F H

“…The effect of the route administration on the distribution of radioiodinated OV-TL 3 F(ab')2 was studied in Balb/c female mice with intraperitoneal or…”
Get full text

Decreased kidney uptake of technetium-99m-labelled Fab' fragments in ovarian carcinoma bearing nude mice using a cleavable chelator by Tibben, J G, Massuger, L F, Boerman, O C, Claessens, R A, Borm, G F, Pak, K Y, Koenders, E B, Corstens, F H

“…A new 99mTc labelling method using a cleavable chelator, RP-1, was developed. In this study Balb/c mice with ovarian carcinoma xenografts received various Fab'…”
Get more information

Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients by Tibben, J G, Thomas, C M, Massuger, L F, Segers, M F, Schijf, C P, Corstens, F H, Boerman, O C

“…The human anti-mouse antibody (HAMA) response was determined in the serum of patients suspected of having ovarian cancer who underwent radioimmunoscintigraphy…”
Get more information

Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer by Tibben, J G, Massuger, L F, Claessens, R A, Schijf, C P, Pak, K Y, Strijk, S P, Kenemans, P, Corstens, F H

“…Fab' fragments of the monoclonal antibody OV-TL 3, that recognizes an ovarian carcinoma-associated antigen (OA3), were labelled with 99Tcm using D-glucarate as…”
Get more information

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab'2) in ovarian carcinoma patients by TIBBEN, J. G, BOERMAN, O. C, MASSUGER, L. F. A. G, SCHIJF, C. P. T, CLAESSENS, R. A. M. J, CORSTENS, F. H. M

Get full text

Results of cyclophosphamide and cisplatin combination chemotherapy in patients with ovarian carcinoma by Tibben, J G, Schijf, C P, Beex, L V

“…An unselected group of 30 patients with advanced epithelial ovarian cancer, FIGO stage IIb-IV, was treated with cyclophosphamide (750 mg/m2) and cisplatin (75…”
Get more information

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients by Tibben, Jacoba G., Boerman, Otto C., Massuger, Leon F. A. G., Schijf, Charles P. T., Claessens, Roland A. M. J., Corstens, Frans H. M.

“…The bispecific monoclonal antibody (biMAb) OC/TR combines the anti‐ovarian‐cancer reactivity of the MOv18 monoclonal antibody (MAb) with the reactivity of an…”
Get full text